New pill targets virus-driven lymphoma in patients who've run out of options

NCT ID NCT06789159

Recruiting now Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 32 times

Summary

This early-phase study tests an experimental daily pill, VK-2019, in 30 adults with a rare type of lymphoma (EBV-positive DLBCL) that has come back or not responded to at least two prior treatments. The main goal is to find the safest dose and see if the drug can control the cancer. Participants take the pill once a day for 28-day cycles until the disease worsens or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Honickman Center
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA RELAPSED EPSTEIN-BARR VIRUS (EBV) INFECTION